NanoViricides: MPox ethics approval enables Phase 2 application
Published: 18:22 16 May 2025 AEST
NanoViricides (NYSE-A:NNVC), a US company, targets the unmet medical need for an effective, broadspectrum acute oral antiviral therapy with NV-387.
Executive summary
A successful African trial could lead to possible development funding from the US biodefense agency (BARDA). Meanwhile, NV has the advantage of its flexible and adaptable anti-viral platform opening potential new opportunities in measles with treatment of bird flu in humans as a possible further indication.
A possible opportunity is in the treatment of Measles. Measles is very well controlled by childhood MMR vaccination; this also guards against other nasty childhood diseases. However, vaccine take up varies between US states and has reduced creating pools of at-risk children. This led to disease reoccurrence (1,001 US cases in 2025 to 9 May with three deaths, CDC). A recent theoretical epidemiology study (JAMA) showed that a drop in vaccination rates could lead to an epidemic.
An effective therapy could therefore be useful as a biosecurity asset. European cases also rose in 2024. In bird flu, NV continues to evaluate the potential for NV-387 as a human therapy against the strain H5N1.
Cases of poultry to human, and some dairy cow to human) transmission are rare but could be a potential threat if human to human transmission occurs. NV’s nano-polymer, micelle technology is designed directly to bind and destroy virus particles in the blood preventing them entering and infecting cells.
NV’s focus is on acute treatment of diseases like Mpox, RSV, flu (including potentially “bird flu”) and COVID-19. NV’s lead molecule NV-387 completed a Phase 1 study in 2023 showing safety and tolerability.
Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) and this website (the Site) on the terms set out in this disclaimer, together with all other terms and conditions, disclaimers and other notices displayed elsewhere on this Site.
It is important for you to know that:
(a) none of the Content is, or is intended to be, general or personal advice
(b) the principal purpose of the Content is to provide factual information only and to comment on news;
(c) the Content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including in respect of any particular security, portfolio of securities, transaction or investment strategy, and must not be relied upon by you as such;
(d) in providing you with the Content, we have not considered your objectives, financial situation or needs; and
(e) you should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
The Content contains data (including but not limited to prices, statistics and calculated information) obtained from a variety of third party sources (Third Party Data). The Company does not make any representation or warranty that any of the Content, including the Third Party Data, will be reliable, accurate or complete. The Company disclaims all responsibility and liability arising in any way from any errors or omissions in the Content, including the Third Party Data, including any loss you may incur in connection with any action or decision made by you in reliance upon the Content or Third Party Data.
In certain circumstances the Company, its related bodies corporate, or their affiliates, may have received, or be entitled to receive, financial or other consideration in connection with providing information about certain entities on the Site, which may include the above Content.
FOR OUR FULL DISCLAIMER CLICK HEREThis document is published by Proactive Research and its contents have not been approved as a financial promotion by Proactive Investors Limited or any other FCA authorised person. This communication is made on the basis of the 'journalist exemption' provide for in Article 20 of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and having regard to the FCA rules, and in particular PERG 8.12.
Where the note contains a ‘buy, sell, hold’ recommend, Proactive Investors Limited is authorised to provide investment advice as defined by Article 53 of the RAO
FOR OUR FULL DISCLAIMER CLICK HERE